8-K filing — Scribe Therapeutics, Inc. (SCTX)
Filed: 2026-11-12 AccNo: 0001193125-26-458486 Size: 402 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Scribe Therapeutics announced its financial results for the third quarter ended September 30, 2026, and provided updates on its clinical pipeline and strategic collaborations.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-11-12 AccNo: 0001193125-26-458486 Size: 402 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Cathie Wood's Ark Invest made selective purchases on Monday, adding to positions in Nvidia, SoFi Technologies, and Scribe Therapeutics despite a generally bullish market day. Nvidia faced headwinds from a spy scandal investigation involving CEO Jensen Huang but remains attractively valued. SoFi showed strong fundamentals with 35% member growth and 44% revenue increase, though it's down 41% over the past year. Scribe Therapeutics, a gene-editing biotech, has sufficient cash runway through early 2029.
ARK Invest has increased its position in Scribe Therapeutics, acquiring 37,246 additional shares as part of a broader portfolio rebalancing in the precision medicine sector.
Scribe Therapeutics management will participate in several healthcare investor conferences and meetings throughout November 2026.
Scribe Therapeutics announced it will present new preclinical data for its lead epigenetic silencing therapy, STX-1150, and its gene editing program, STX-1200, at the American Heart Association's Scientific Sessions.
Biocom California named Ioana Aanei, director of business development and alliance management at Scribe Therapeutics, as one of the 13 winners of its 2026 Life Science Catalyst Awards.